PACS Group, Inc. (PACS) SEC Filings & Earnings Calls
EquiReason read 20 PACS Group, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-21 — Chief Legal Officer John Mitchell retired; Patrick J. Murphy appointed as successor; Mitchell to serve as consultant for up to 12 months with severance..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 7.5B
- P/E TTM
- 27.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QPACS reported strong Q2 2026 results with revenue up 9.1% YoY, net income up 49.8%, and same-store occupancy improving 150 bps.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.43B | +9% y/y |
| Net income · Q2-2026 | $76M | +50% y/y |
| Adjusted EBITDA · Q2-2026 | $167M | +25% y/y |
| Occupancy rate (operational beds) · Total skilled nursing · Q2-2026 | 90.4% | |
| Skilled nursing services revenue · Total skilled nursing · Q2-2026 | $1.38B | +8% y/y |
| Skilled mix by revenue · Total skilled nursing · Q2-2026 | 50.0% | |
| Number of facilities · Total post-acute care · Q2-2026 | 324 | +3% y/y |
| Operating cash flow · H1-2026 | $372M | +83% y/y |
Risks flagged
Regulatory and compliance risk
“The SNF industry is highly regulated with stringent regulatory compliance obligations.” · word for word
Liability insurance cost increase
“increase in liability insurance of $26.2 million” · word for word
Legal and investigation costs
“Legal and other costs 8,167 24,060 19,944 46,864” · word for word
4 Aug 20268-K · 2.02Revenue $1.43B (+9% y/y); Net income $76M (+50% y/y); Adjusted EBITDA $167M (+25% y/y); Guidance: FY2026 Adjusted EBITDA $640-$660M (from $605-$625M); Revenue $5.75-$5.85B (from $5.65-$5.75B)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.43B | +9% y/y |
| Net income · Q2-2026 | $76M | +50% y/y |
| Adjusted EBITDA · Q2-2026 | $167M | +25% y/y |
Guidance
FY2026 Adjusted EBITDA $640-$660M (from $605-$625M); Revenue $5.75-$5.85B (from $5.65-$5.75B)
Raised full-year guidance across revenue and EBITDA, reflecting strong operational performance and acquisition pipeline.
Risks flagged
Regulatory and reimbursement risks in skilled nursing industry.
“Industry average occupancy 79.5% vs company 90.4%; regulatory environment.”
11 May 202610-QRevenue $1.42B (+11% y/y); Net Income $81M (+184% y/y); Adjusted EBITDA $170M (+75% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.42B | +11% y/y |
| Net Income · Q1-2026 | $81M | +184% y/y |
| Adjusted EBITDA · Q1-2026 | $170M | +75% y/y |
| Occupancy · Q1-2026 | 90.8% | |
| Skilled Mix by Revenue · Q1-2026 | 50.7% | |
| Operating Cash Flow · Q1-2026 | $236M | +57% y/y |
Risks flagged
Regulatory and Compliance Risk
“The SNF industry is highly regulated with stringent regulatory compliance obligations.” · word for word
Credit Facility Covenant Risk
“We entered into forbearance agreements and amendments to the Amended and Restated Credit Facility due to technical events of default.”
California Concentration Risk
“Our California operations represent our largest geographic concentration, comprising 140 facilities and 16,132 beds/units, or approximately 43% and 45%, respectively, of our total facilities and beds/units.” · word for word
Labor Cost Pressure
“Cost of services increased by $50.7 million, primarily driven by an increase of $39.5 million, or 6.2%, in salaries and wages.”
11 May 20268-K · 2.02Revenue $1.42B (+11% y/y); Net income $81M (+184% y/y); Adjusted EBITDA $170M (+75% y/y); Guidance: Full-year 2026 Adj. EBITDA guidance raised to $605-625M from $555-575Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.42B | +11% y/y |
| Net income · Q1-2026 | $81M | +184% y/y |
| Adjusted EBITDA · Q1-2026 | $170M | +75% y/y |
| Occupancy · Q1-2026 | 90.8% | |
| Skilled mix · Q1-2026 | 30.5% | |
| Cash provided by operating activities · Q1-2026 | $236M |
Guidance
Full-year 2026 Adj. EBITDA guidance raised to $605-625M from $555-575M
Strong Q1 beat drives upward revision to full-year EBITDA guidance.
Risks flagged
Guidance excludes future acquisitions, which may limit growth visibility.
“updated guidance excludes contributions from future acquisitions” · word for word
WQIP payments of $16.3M are non-recurring in nature.
“includes approximately $16.3 million of net EBITDA benefit from payments received under California’s Workforce & Quality Incentive Program” · word for word
28 Apr 2026DEF 14AProxy statement with strong financial performance, executive compensation disclosure, and clawback recovery details.open
Figures in the filing · each found in the filing text
| Net Income · FY2025 | $191M | |
| Adjusted EBITDA · FY2025 | $505M | |
| Total Shareholder Return · FY2025 | $167.00 | |
| Compensation Actually Paid to PEO · FY2025 | $18M | |
| Average Compensation Actually Paid to non-PEO NEOs · FY2025 | $22M |
Risks flagged
Financial Restatement Risk
“The Audit Committee conducted an independent internal investigation of third-party allegations contained in a short-seller report published in November 2024.” · word for word
Controlled Company Governance Risk
“We are a 'controlled company' under the rules of the NYSE. As of the Record Date, Messrs. Murray and Hancock beneficially own approximately 70% of the combined voting power of our outstanding capital stock.” · word for word
27 Apr 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
CFO transition risk, mitigated by planned succession and experienced appointee.
“CFO change with interim period ending.”
27 Feb 202610-KNumber of Facilities 321; Daily Patient Census 31,700; Occupancy Rate (Mature Facilities) 95open
Figures in the filing · each found in the filing text
| Number of Facilities · FY2025 | 321 | |
| Daily Patient Census · FY2025 | 31,700 | |
| Occupancy Rate (Mature Facilities) · Mature · FY2025 | 95.0% | |
| QM Star Rating (Mature Facilities) · Mature · FY2025 | $4.40 | +2% y/y |
| Skilled Mix by Nursing Patient Days · FY2025 | 29.0% | |
| Number of Employees · FY2025 | 47,455 |
Risks flagged
Reimbursement Risk from Government Payors
“We depend upon reimbursement from third‑party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our facilities as well as changes in payor mix and payment methodologies.” · word for word
Labor Shortage and Wage Inflation
“Increased competition for, or a shortage of, nurses, nurse assistants and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.” · word for word
Regulatory Compliance and Enforcement
“Our policy is to comply with laws prohibiting kickbacks and referral payments to referral sources. If our competitors use more aggressive methods than we do with respect to obtaining patient referrals, our competitors may from time to time obtain patient referrals that are not otherwise available to us.” · word for word
26 Feb 20268-K · 2.02Revenue $5.29B (+29% y/y); Net income $192M; Adjusted EBITDA $505M; Guidance: 2026 revenue $5.65-5.75B, EBITDA $555-575Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $5.29B | +29% y/y |
| Net income · FY2025 | $192M | |
| Adjusted EBITDA · FY2025 | $505M | |
| Mature facilities occupancy · Skilled Nursing · FY2025 | 94.9% | |
| Mature facilities skilled mix · Skilled Nursing · FY2025 | 33.4% | |
| Cash provided by operating activities · FY2025 | $404M |
Guidance
2026 revenue $5.65-5.75B, EBITDA $555-575M
Guidance implies continued growth driven by acquisitions and occupancy.
1 Dec 20258-K · 1.01Minimum cash covenant $100Mopen
Figures in the filing · each found in the filing text
| minimum cash covenant · Q4-2025 | $100M |
Risks flagged
Default waiver and covenant modification indicate elevated financial risk and potential liquidity constraints.
“Waived all defaults and events of default; cash covenant modified to only apply until June 30, 2026.” · word for word
25 Nov 2025DEF 14APACS Group filed a DEF 14A proxy statement disclosing executive compensation tied to Adjusted EBITDA, a financial restatement triggering clawback of $3.84M, and high insider ownership.open
Figures in the filing · each found in the filing text
| Net income · FY2024 | $55M | -51% y/y |
| Adjusted EBITDA · FY2024 | $280M | +18% y/y |
| Total Shareholder Return · 2024-04-11 to 20 | $57.00 | |
| Peer Group Total Shareholder Return · 2024-04-11 to 20 | $116.06 | |
| Shares Outstanding · 2025-11-10 | 156,615,444 |
Risks flagged
Financial Restatement Risk
“the Audit Committee determined that (i) our condensed combined/consolidated financial statements as of March 31, 2024, and for the three months then ended, included in our Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024 (as amended on May 21, 2024) and (ii) our condensed combined/consolidated financial statements as of June 30, 2024, should ” · word for word
Insider Control Risk
“All Executive Officers and Directors as a Group (8 individuals) 110,320,631 70.4%” · word for word
Clawback Enforcement Risk
“the aggregate amount that remains outstanding is $1,227,019. ... The Compensation Committee will seek to recover the remaining amount of the erroneously awarded compensation from each of Messrs. Murray and Hancock in accordance with the Clawback Policy.” · word for word
19 Nov 20258-K · 2.02Revenue $1.34B (+31% y/y); Net income $52M; Adjusted EBITDA $132M; Guidance: FY2025 revenue $5.25-5.35B, Adj. EBITDA $480-490Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.34B | +31% y/y |
| Net income · Q3-2025 | $52M | |
| Adjusted EBITDA · Q3-2025 | $132M | |
| Adjusted EBITDAR · Q3-2025 | $227M | |
| Revenue · YTD-2025 | $3.93B | +36% y/y |
| Net income · YTD-2025 | $132M | |
| Adjusted EBITDA · YTD-2025 | $363M | |
| Adjusted EBITDAR · YTD-2025 | $646M | |
| Revenue · FY2024 | $4.09B | +31% y/y |
| Net income · FY2024 | $55M |
Guidance
FY2025 revenue $5.25-5.35B, Adj. EBITDA $480-490M
Guidance raised for FY2025 reflecting strong demand and operational execution.
Risks flagged
Restatement and investigation completed, but prior accounting issues may indicate control weaknesses.
“Completes Restatement of Previously Issued Financial Statements and Now Current with SEC Filing Obligations. Audit Committee completes investigation.” · word for word
19 Nov 202510-QPACS reported strong revenue growth of 39.9% YoY and net income of $51M vs a loss last year, but disclosed credit facility forbearance and rising legal costs.earningsopen
Figures in the filing · each found in the filing text
| Skilled mix by revenue · Total · Q2-2025 | 49.4% | |
| Occupancy rate (operational beds) · Total · Q2-2025 | 88.6% | |
| Adjusted EBITDA · Q2-2025 | $134M | +115% y/y |
| Net income · Q2-2025 | $51M | +260% y/y |
| Operating cash flow · H1-2025 | $203M | +117% y/y |
Risks flagged
Credit facility forbearance and technical defaults
“We are in a state of forbearance with the lenders associated with the Amended and Restated Credit Facility and as a result, we are currently unable to borrow additional amounts.” · word for word
Legal and regulatory investigations
“Legal and other costs include legal and professional fees incurred associated with the Audit Committee’s independent investigation and with other ongoing investigations.” · word for word
Occupancy decline in new and ramping facilities
“New and Ramping facilities experienced a decrease in occupancy, from 84.2% and 94.4%, respectively, for the three months ended June 30, 2024 to 80.5% and 86.1%, respectively, for the three months ended June 30, 2025” · word for word
19 Nov 202510-Q9M 2025 earnings: revenue +36.4% YoY, net income +587.5% YoY, but credit facility in forbearance and legal costs elevated.earningsopen
Figures in the filing · each found in the filing text
| Occupancy rate (operational beds) · 9M-2025 | 88.9% | |
| Skilled mix by revenue · 9M-2025 | 49.1% | |
| Net income · 9M-2025 | $132M | +588% y/y |
| Adjusted EBITDA · 9M-2025 | $363M | +96% y/y |
| Operating cash flow · 9M-2025 | $408M | +35% y/y |
Risks flagged
Credit facility forbearance and technical defaults
“During the forbearance period, we are required to comply with certain additional specified conditions, including the continued maintenance of minimum liquidity of $100 million, limitations on certain investments and acquisitions, and a prohibition on the borrowing of new loans under the Amended and Restated Credit Facility.” · word for word
Government investigations and legal costs
“Legal and other costs 66,460 for the nine months ended September 30, 2025.”
Medicaid funding cuts under OBBBA
“The OBBBA imposes significant reductions in the funding of the Medicaid program, such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid.” · word for word
19 Nov 202510-QQ3 2025 earnings: revenue +31% YoY, net income +223% YoY, but credit facility in forbearance and legal costs elevated.earningsopen
Figures in the filing · each found in the filing text
| Occupancy rate (operational beds) · Q3-2025 | 89.0% | |
| Skilled mix by revenue · Q3-2025 | 48.0% | |
| Net income · Q3-2025 | $52M | +223% y/y |
| Adjusted EBITDA · Q3-2025 | $132M | +168% y/y |
| Operating cash flow · 9M-2025 | $408M | +35% y/y |
Risks flagged
Credit facility forbearance and technical defaults
“During the forbearance period, we are required to comply with certain additional specified conditions, including the continued maintenance of minimum liquidity of $100 million, limitations on certain investments and acquisitions, and a prohibition on the borrowing of new loans under the Amended and Restated Credit Facility.” · word for word
Government investigations and legal costs
“Legal and other costs 19,596 for the three months ended September 30, 2025.”
Medicaid funding cuts under OBBBA
“The OBBBA imposes significant reductions in the funding of the Medicaid program, such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid.”
19 Nov 202510-QPACS reported strong revenue growth of 38.8% YoY but net income declined 18.5% due to rising legal costs, and disclosed credit facility forbearance.earningsopen
Figures in the filing · each found in the filing text
| Skilled mix by revenue · Total · Q1-2025 | 50.0% | |
| Occupancy rate (operational beds) · Total · Q1-2025 | 89.2% | |
| Adjusted EBITDA · Q1-2025 | $98M | +32% y/y |
| Net income · Q1-2025 | $28M | -19% y/y |
| Operating cash flow · Q1-2025 | $150M | +156% y/y |
Risks flagged
Credit facility forbearance and technical defaults
“We are in a state of forbearance with the lenders associated with the Amended and Restated Credit Facility and as a result, we are currently unable to borrow additional amounts.” · word for word
Legal and regulatory investigations
“Legal and other costs include legal and professional fees incurred associated with the Audit Committee’s independent investigation and with other ongoing investigations.” · word for word
Occupancy decline in new and ramping facilities
“New facilities experienced a slight decrease in occupancy, from 83.3% for the three months ended March 31, 2024 to 81.8% for the three months ended March 31, 2025” · word for word
19 Nov 202510-KRevenue $4.10B (+32% y/y); Net Income $55M (-51% y/y); Adjusted EBITDA $280M (+18% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Consolidated · FY2024 | $4.10B | +32% y/y |
| Net Income · Consolidated · FY2024 | $55M | -51% y/y |
| Adjusted EBITDA · Consolidated · FY2024 | $280M | +18% y/y |
| Occupancy Rate (Mature) · Mature Facilities · FY2024 | 94.0% | |
| Occupancy Rate (Overall) · Consolidated · FY2024 | 90.0% | |
| QM Star Rating (Mature) · Mature Facilities · FY2024 | $4.30 | +2% y/y |
| Skilled Mix by Revenue (Mature) · Mature Facilities · FY2024 | 54.0% | |
| Skilled Mix by Nursing Patient Days · Consolidated · FY2024 | 29.0% | |
| Number of Facilities · Consolidated · FY2024 | 314 | |
| Number of Employees · Consolidated · FY2024 | 45,680 |
Risks flagged
Dependence on government reimbursement
“A substantial portion of our revenue is generated from payments from third-party payors, including Medicare and Medicaid, which represent our largest sources of revenue and accounted for 33.8% and 40.4% of our routine revenue for the year ended December 31, 2024, respectively.” · word for word
Regulatory compliance and enforcement risk
“We operate in a highly regulated industry with stringent regulatory compliance obligations, which require robust regulatory compliance operations. Failure to operate in compliance with applicable laws and regulations could require significant expenditures and result in regulatory deficiencies and other regulatory penalties.” · word for word
6 Nov 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Delisting risk from NYSE due to delinquent filings.
“NYSE deadline November 19, 2025; company not current.”
Forbearance extension indicates potential covenant breach or default.
“Forbearance agreement with lenders and landlord extended to Nov 30, 2025.”
Ongoing Audit Committee investigation may reveal further issues.
“Risks relating to ongoing Audit Committee investigation.”
PACS Group, Inc. — questions
- What did PACS Group, Inc. file recently?
- 20 SEC filings in the last 12 months. Latest: 8-K on 2026-09-21 — Chief Legal Officer John Mitchell retired; Patrick J. Murphy appointed as successor; Mitchell to serve as consultant for up to 12 months with severance.
Every figure on this page comes from PACS Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.